CEP-7055 - CAS 402857-58-3
Catalog number:
402857-58-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Description:
CEP-18770 is An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
CEP-7055;
MSDS:
Inquire
Current Developer:
Cephalon and sanofi-aventis
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 402857-58-3 CEP-7055

Quick Inquiry

Verification code

Featured Items